Dimethyltriazenoimidazolecarboxamide
Dimethyltriazenoimidazolecarboxamide Brand names, Dimethyltriazenoimidazolecarboxamide Analogs
Dimethyltriazenoimidazolecarboxamide Brand Names Mixture
- No information avaliable
Dimethyltriazenoimidazolecarboxamide Chemical_Formula
C6H10N6O
Dimethyltriazenoimidazolecarboxamide RX_link
http://www.rxlist.com/cgi/generic2/dacarbazine.htm
Dimethyltriazenoimidazolecarboxamide fda sheet
Dimethyltriazenoimidazolecarboxamide msds (material safety sheet)
Dimethyltriazenoimidazolecarboxamide Synthesis Reference
Zambito et al.; Nucleic Acid Chem.; 1978; 3,8,9,10(1978);.
Dimethyltriazenoimidazolecarboxamide Molecular Weight
182.183 g/mol
Dimethyltriazenoimidazolecarboxamide Melting Point
205 oC
Dimethyltriazenoimidazolecarboxamide H2O Solubility
4220 mg/L
Dimethyltriazenoimidazolecarboxamide State
Solid
Dimethyltriazenoimidazolecarboxamide LogP
-1.938
Dimethyltriazenoimidazolecarboxamide Dosage Forms
Liquid; Powder for solution
Dimethyltriazenoimidazolecarboxamide Indication
For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents
Dimethyltriazenoimidazolecarboxamide Pharmacology
After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.
Dimethyltriazenoimidazolecarboxamide Absorption
Erratic, slow and incomplete
Dimethyltriazenoimidazolecarboxamide side effects and Toxicity
LD50=350mg/kg (orally in mice)
Dimethyltriazenoimidazolecarboxamide Patient Information
This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the way
cancer cells grow, Take your doses on a regular scheduled time and DO
NOT take this medicine more often than directed by your health care
provider. Finish the full course prescribed by your health care provider.
DO NOT stop taking this medicine unless diredted to do so by your health
care provider. While taking this medicine, you make get infection more
easily. Call your doctor if you get a fever, chills, or sore throat.
Drink plenty of water with this medicine.
blood and certain other cancers. This medicine interfers with the way
cancer cells grow, Take your doses on a regular scheduled time and DO
NOT take this medicine more often than directed by your health care
provider. Finish the full course prescribed by your health care provider.
DO NOT stop taking this medicine unless diredted to do so by your health
care provider. While taking this medicine, you make get infection more
easily. Call your doctor if you get a fever, chills, or sore throat.
Drink plenty of water with this medicine.
Dimethyltriazenoimidazolecarboxamide Organisms Affected
Humans and other mammals
